ArticleBreast cancer research and treatment2012
Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells.
Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02824835 (The Effect of the Plant Hormones Strigolactones on Cultures of Dysplastic Colonic Lesions and Cancer), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of the Plant Hormones Strigolactones on Cultures of Dysplastic Colonic Lesions and Cancer
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Recent Advancements in Pentacyclic and Other Terpenoid Derivatives as Anti-inflammatory Agents.Mini reviews in medicinal chemistry · 2026Review
- Interaction between the breast tumor microenvironment and gut microbiome.Gut microbes · 2025Review
- Allies or Enemies? The Power of Plant Hormones in Animals: Insights into Their Regulatory Roles.Molecules (Basel, Switzerland) · 2025Review
- A multifaceted assessment of strigolactone GR24 and its derivatives: from anticancer and antidiabetic activities to antioxidant capacity and beyond.Frontiers in molecular biosciences · 2023Review
- On the human health benefits of microalgal phytohormones: An explorativeComputational and structural biotechnology journal · 2023Article
- Strigolactone Analogs: Two New Potential Bioactiphores for Glioblastoma.ACS chemical neuroscience · 2022Article
- Strigolactones, from Plants to Human Health: Achievements and Challenges.Molecules (Basel, Switzerland) · 2021Review
- Strigolactone Analogs Are Promising Antiviral Agents for the Treatment of Human Cytomegalovirus Infection.Microorganisms · 2020Article
- Cellular Plasticity in Breast Cancer Progression and Therapy.Frontiers in molecular biosciences · 2020Review
- Identification of a Strigoterpenoid with Dual Nrf2 and Nf-κB Modulatory Activity.ACS medicinal chemistry letters · 2019Article
- Gene Ontology and Expression Studies of Strigolactone Analogues on a Hepatocellular Carcinoma Cell Line.Analytical cellular pathology (Amsterdam) · 2019Article
- Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells.Oncotarget · 2018Article
- Strigolactones-a novel class of phytohormones as anti-cancer agents.Journal of pesticide science · 2018Article
- Strigolactones: a plant phytohormone as novel anti-inflammatory agents.MedChemComm · 2018Article
- Breast tissue, oral and urinary microbiomes in breast cancer.Oncotarget · 2017Article
- Cancer stem cells and chemoresistance: The smartest survives the raid.Pharmacology & therapeutics · 2016Review
- Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.Oncotarget · 2016Article
- Plant derived substances with anti-cancer activity: from folklore to practice.Frontiers in plant science · 2015Review
- Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model.Cancer biology & therapy · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Several naturally occurring phytohormones have shown enormous potential in the prevention and treatment of variety of different type of cancers. Strigolactones (SLs) are a novel class of plant hormones produced in roots and regulate new above ground shoot branching, by inhibiting self-renewal of undifferentiated meristem cells. Here, we study the effects of six synthetic SL analogs on breast cancer cell lines growth and survival. We show that SL analogs are able to inhibit proliferation and induce apoptosis of breast cancer cells but to a much lesser extent "non-cancer" lines. Given the therapeutic problem of cancer recurrence which is hypothesized to be due to drug resistant cancer stem cells, we also tested the ability of SL analogs to inhibit the growth of mammosphere cultures that are typically enriched with cancer stem-like cells. We show that SLs are potent inhibitors of self-renewal and survival of breast cancer cell lines grown as mammospheres and even a short exposure leads to irreversible effects on mammosphere dissociation and cell death. Immunoblot analysis revealed that SLs analogs induce activation of the stress response mediated by both P38 and JNK1/2 MAPK modules and inhibits PI3K/AKT activation. Taken together this study indicates that SLs may be promising anticancer agents whose activities may be achieved through modulation of stress and survival signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.